Glassberg Andrea E, Luce John M, Matthay Michael A
Permanente Medical Group, Fremont, San Francisco, San Francisco, CA.
University of California, San Francisco, San Francisco, CA.
Chest. 2008 Oct;134(4):719-723. doi: 10.1378/chest.08-0633. Epub 2008 Aug 8.
Enrolling critically ill patients in clinical trials is challenging. We observed that eligible patients at San Francisco General Hospital (SFGH), a public hospital that cares largely for indigent patients, were less likely to be enrolled in a clinical trial of acute lung injury (ALI) than eligible patients at the University of California, San Francisco (UCSF), a university referral center. We examined the reasons for nonenrollment and the impact of the availability of a surrogate decision maker on critical care clinical trials enrollment.
Data collected from the ARDS Network trial of lower vs traditional tidal volume ventilation for patients with ALI was analyzed. Patient demographics and reasons for nonenrollment were analyzed among 531 consecutively screened patients at the two hospitals: UCSF and SFGH.
At UCSF, 1% of screened patients were not enrolled because they lacked surrogates, whereas 18% of screened patients were not enrolled at SFGH because they lacked surrogates. Lack of surrogate was the most common reason for nonenrollment among eligible patients at SFGH.
Critically ill patients with ALI at a public hospital were less likely to be enrolled in a clinical trial than patients at a university hospital primarily because they lacked surrogates. Lack of a surrogate also was a major factor in nonenrollment in other ARDS Network hospitals. In order to provide all affected patients an opportunity to participate in research, innovative strategies for increasing enrollment in critical care research without compromising protection from research risks are needed.
将重症患者纳入临床试验具有挑战性。我们观察到,旧金山总医院(SFGH)主要收治贫困患者,与大学转诊中心加州大学旧金山分校(UCSF)的合格患者相比,SFGH的合格患者参加急性肺损伤(ALI)临床试验的可能性较小。我们研究了未入组的原因以及替代决策者的可获得性对重症监护临床试验入组的影响。
分析了急性呼吸窘迫综合征网络(ARDS Network)针对ALI患者进行低潮气量通气与传统潮气量通气试验所收集的数据。对UCSF和SFGH这两家医院连续筛查的531例患者的人口统计学数据和未入组原因进行了分析。
在UCSF,1%的筛查患者因缺乏替代决策者而未入组,而在SFGH,18%的筛查患者因缺乏替代决策者而未入组。缺乏替代决策者是SFGH合格患者中最常见的未入组原因。
公立医院的ALI重症患者比大学医院的患者参加临床试验的可能性小,主要原因是他们缺乏替代决策者。缺乏替代决策者也是其他ARDS Network医院未入组的主要因素。为了让所有受影响的患者都有机会参与研究,需要采取创新策略来增加重症监护研究的入组人数,同时又不影响对研究风险的防范。